Enhancing T Cell Capacity & Sensitizing Tumors for T Cell Killing by TME Gene Engineering to Enhance ICI & TIL Therapy
Time: 9:00 am
day: Day Two
Details:
• How TME gene engineering can activate, stimulate and attract T and NK cells to the TME though chemokine release and transmigration from blood vessels, invoking antitumor immunity, and enhancing tumor cell immunogenicity
• How TME gene engineered vectors can be administered with ICIs to treat solid tumors, supported by clinical data
• How TME gene engineered vectors can be combined with adoptive T cell therapy can enhance patient response, supported by preclinical data
